Keywords:-

Keywords: ischemic stroke ; electrical shock ; atrial fibrillation ; apixaban

Article Content:-

Abstract

This article discusses the case of a patient with ischemic stroke following a cardioversion of Atrial Fibrillation under treatment with Apixaban 5 mg twice daily.

Adherence to anticoagulant therapy and normal trans-thoracic ultrasound do not eliminate the possibility of an atrial thrombus, which may contraindicate or delay the cardioversion procedure. The use of transesophageal echocardiography in this case is discussed, to avoid the occurrence of thromboembolic events.

This study indicates the need for further studies whether for flutter ablations or cardioversions under oral anticoagulants.

References:-

References

Hagg L, Johansson C, Jansson JH, Johansson L. External validity of the ARISTOTLE trial in real-life atrial fibrillation patients. Cardiovasc Ther 2014;32:214—8.

Daily Med, Current Medication Information, Rivaroxaban, http://dailymed. nlm. nih. gov/ dailymed.

Daily Med, Current Medication Information, Apixaban http://dailymed.nlm.nih.gov/dailymed

Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet 2013,4 :243-54.

Daily Med, Current Medication Information, Dabigatran Etexilate Mesylate,

http://dailymed.nlm.nih.gov/dailymed

Jan Václavík , Dabigatran antidote idarucizumab has come to clinical practice, cor et vasa 58 (2016) e1–e3

Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-962.

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hyulek EM,Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981—92.

Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992;19:851-5.

Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embo- lism related to DC electrical conversion of atrial fibrillation. Am J Cardiol 1969;23:208-16.

Roy D, Marchand E, Gagné P, Chabot M, Cartier R. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J 1986;112:1039-43.

Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B et al. Efficacy and safety of apixaban in patients following cardioversion for atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol 2014;63:1082-7.

Heidbuchel H, Verhamme P, Alings M, et al. EHRA updated practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation, Europace. 2015 Oct; 17(10): 146-507

P. Albaladejo , D. Deplanque et al Bon usage d’apixaban : que retenir pour la pratique, Journal des Maladies Vasculaires Volume 39, Issue 6, December 2014, Pages 409-425.

Downloads

Citation Tools

How to Cite
NADIF, M., BENNANI, M., FAID, S., SRIFI, D., Manouri, K., Ahchouch, S., Kheyi, J., Bouzelmat, H., Lakhal, Z., & Chaib, A. (2018). A Case Report of an Ischemic Stroke after Electrical Shock of Atrial Fibrillation Under Apixaban. RA Journal Of Applied Research, 4(11), 2116-2119. https://doi.org/10.31142/rajar/v4i11.03